The U.S. Food & Drug Administration (FDA) has recently ruled on the use of PFAS in medical devices, stating that there is “no conclusive evidence of patient health issues associated with PTFE as a material.”
PFAS – per- and polyfluoroalkyl substances – have garnered intense public scrutiny in recent years. With evolving regulation and heightened concern for environmental and patient safety, it’s vital to understand their role in medical devices. This blog clarifies the FDA’s latest stance, highlights why PFAS materials remain crucial in healthcare, and underscores SSG’s leadership in responsibly navigating this complex regulatory landscape.
Not All PFAS Are the Same
PFAS represent a vast family – more than 15,000 chemicals used across industries – but they are not interchangeable. Some small-molecule PFAS have been linked to health and environmental concerns. Conversely, the PFAS employed in medical devices are large-molecule fluoropolymers, such as PTFE, in use since the 1950s. The FDA currently finds no justification for restricting the use of PFAS in medical devices – a position that aligns with SSG’s advocacy for nuanced, science-based distinctions rather than outright bans.
Fluoropolymers: Critical to Medical Device Performance
Fluoropolymers deliver indispensable properties in life-saving medical devices – including cardiovascular stents, pacemaker leads, vascular grafts, and guidewires—by offering lubrication, electrical insulation, and long-term biostability. Their molecular size prevents passage through cell membranes, minimizing toxicity risk. When combined with the FDA’s position and SSG’s commitment to safe, effective coatings, it becomes clear: fluoropolymers remain unmatched in enabling device performance while prioritizing patient safety.
FDA Safety Review: Reassuring and Rigorous
In a landmark collaborative review with ECRI, the FDA examined over 1,750 peer-reviewed studies and collected data from over 1,800 U.S. healthcare organizations. The 2021 findings revealed no conclusive evidence linking PTFE to adverse patient effects, effectively supporting its continued use. This evidence-based reassurance resonates with SSG’s responsible advocacy to clear up common myths about PTFE and PFAS.
Read the FDA’s article about the use of PFAS in medical devices for more information.
Contact SSG to speak with a technical consultant to learn more about the FDA’s ruling and what it means for your medical device project.